Dechra buys pet stem-cell developer Gallant as FDA decision nears
What's the deal? Dechra PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has agreed to acquire Gallant Pet, a San Diego biotech developing ready-to-use stem-cell therapies for dogs and cats. Terms are confidential, and the deal, announced in November 2026, still faces customary closing conditions.
What does Gallant do? It makes donor-derived mesenchymal stromal cell (MSC) therapies that a vet can take from a freezer and give by IV, with no tissue harvest from the patient. Its pipeline spans feline chronic gingivostomatitis, osteoarthritis in both species, feline chronic kidney disease, and canine atopic dermatitis.
Why now? Gallant's lead product, sonruvetcel, for cats with refractory chronic gingivostomatitis, is close to a regulatory decision. The Food and Drug Administration's Center for Veterinary Medicine has signed off on both the effectiveness and 365-day safety sections of its conditional approval file.
In a pivotal study, over 75% of treated cats showed a clinically relevant gain in quality of life by day 90. Gallant says that, if approved, sonruvetcel would be the first FDA-labelled, off-the-shelf stem-cell therapy in veterinary medicine.
What's the endgame? The acquisition extends Dechra's push into companion-animal biologics. In 2024 it agreed to buy Invetx for up to $520 million, adding long-acting antibody programs for osteoarthritis and atopic dermatitis; Gallant brings a distinct cell-therapy modality with overlapping disease targets.
Gallant also brings manufacturing capability. Its San Diego facility complies with Good Manufacturing Practices, and the company has signed MWI Animal Health, part of CencoraDealroom has a profile for this one. Try Dealroom →, to run what it calls the first ultra-low-temperature cold chain in veterinary medicine.
What could go wrong? The value is not assured. Sonruvetcel still awaits a conditional approval that Gallant once targeted for early 2026, then pushed to later in the year, and the therapies must be manufactured and delivered reliably at scale.
Dechra called the purchase "complementary" and said it fits its strategy to "serve unmet needs in specialty care." Gallant raised an $18 million Series B in June 2025, led by Digitalis VenturesDealroom has a profile for this one. Try Dealroom →, though that round offers no guide to the undisclosed acquisition price.
The signal: Veterinary medicine is drawing the same biologics and cell-therapy bets long seen in human health. For Dechra, buying a developer with a near-regulatory product, a built cold chain, and a broad pipeline is a step toward owning novel treatment modalities before rivals do.
Read more: devcuration.com
Image credit: Anne Worner
